HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Céline Martel Selected Research

Intravaginal Administration

11/2018Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
1/2017Science of intracrinology in postmenopausal women.
5/2016Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
3/2016Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
1/2016Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
11/2015Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
5/2015Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
11/2013Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
9/2008Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Céline Martel Research Topics

Disease

24Atrophy
11/2018 - 09/2008
8Dyspareunia
11/2018 - 07/2014
7Pain (Aches)
11/2018 - 09/2009
5Breast Neoplasms (Breast Cancer)
07/2012 - 04/2005
3Prostatic Neoplasms (Prostate Cancer)
10/2012 - 04/2007
2Carcinoma (Carcinomatosis)
10/2012 - 02/2003
1Coronary Disease (Coronary Heart Disease)
01/2011
1Endometrial Neoplasms (Endometrial Cancer)
01/2010
1Uterine Neoplasms (Uterine Cancer)
01/2009
1Osteoporosis
06/2006
1Obesity
06/2006
1Type 2 Diabetes Mellitus (MODY)
06/2006
1Hypertension (High Blood Pressure)
04/2002
1Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
02/2002

Drug/Important Bio-Agent (IBA)

24Dehydroepiandrosterone (DHEA)IBA
11/2018 - 09/2008
10Estrogens (Estrogen)FDA Link
01/2017 - 02/2002
7SteroidsIBA
01/2018 - 01/2009
5AndrogensIBA
01/2017 - 06/2006
4Estradiol (Delestrogen)FDA LinkGeneric
11/2017 - 04/2005
3Androgen Antagonists (Antiandrogens)IBA
10/2012 - 04/2007
3Hormones (Hormone)IBA
07/2012 - 01/2009
2Testosterone (Sustanon)FDA Link
11/2013 - 04/2002
1Conjugated (USP) Estrogens (Premarin)FDA Link
11/2017
1Pharmaceutical PreparationsIBA
11/2017
1Suppositories (Vaginal Suppositories)IBA
01/2016
1EnzymesIBA
12/2015
1nilutamide (Nilandron)FDA Link
10/2012
1bicalutamide (Casodex)FDA LinkGeneric
10/2012
1AntigensIBA
10/2012
1Flutamide (Eulexin)FDA LinkGeneric
10/2012
1Indicators and Reagents (Reagents)IBA
10/2012
1Gonadotropin-Releasing Hormone (GnRH)FDA Link
10/2012
1Androgen Receptors (Androgen Receptor)IBA
10/2012
1Estrogen ReceptorsIBA
04/2005
1LipidsIBA
02/2003
1Selective Estrogen Receptor Modulators (SERM)IBA
02/2003

Therapy/Procedure

9Intravaginal Administration
11/2018 - 09/2008
2Castration
10/2012 - 01/2009
2Drug Therapy (Chemotherapy)
07/2012 - 05/2009
2Therapeutics
07/2012 - 01/2009
1Ovariectomy (Oophorectomy)
01/2011
1Radiotherapy
05/2009